Gilead, Roche infectious news

ROCZ will pay GILD $62.5 million in adjusted royalties to settle a dispute related to a 1996 deal under which GILD granted ROCZ rights to influenza drug Tamiflu oseltamivir. The companies also agreed to establish joint committees to oversee manufacturing, commercial and pandemic planning for the oral neuraminidase inhibitor. The settlement also gives GILD the option to co-promote Tamiflu in "specialized areas" in the U.S. In addition, GILD said it will now receive royalties at the companies' "contractually specified" rate, which is based on the level of Tamiflu sales and ranges from 14-22%. Previously, GILD said it was receiving royalties that included adjustments for cost of goods. ...